Alembic Pharmaceuticals announced that the company has received
approval from the US Food & Drug Administration (USFDA) for its Abbreviated New
Drug Application (ANDA) Tobramycin Ophthalmic Solution USP, 0.3%. The approved
ANDA is therapeutically equivalent to the reference listed drug (RLD), Tobrex
Ophthalmic Solution, 0.3%, of Novartis Pharmaceuticals Corporation. Tobramycin
Ophthalmic Solution USP, 0.3% is a topical antibiotic indicated in the treatment of
external infections of the eye and its adnexa caused by susceptible bacteria.
Tobramycin Ophthalmic Solution USP, 0.3% have an estimated market size of US$ 9.6 million for twelve months ending December 2018 according to IQVIA.
Alembic now has a total of 92 ANDA approvals (80 final approvals and 12 tentative approvals) from USFDA.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
